Literature DB >> 12084216

Kidney pathology: current classification of renal cell carcinoma.

Jonathan W Said1, George Thomas, Amnon Zisman.   

Abstract

This report discusses the new cytogenetic classification of renal cell carcinoma (RCC) and its biological and clinical significance. It describes the four major types (clear cell, chromophil, chromophobe, and collecting duct) as well as rarer entities, such as small cell carcinoma, cystic RCC, rhabdoid variant of RCC, and unclassified RCC. Sarcomatoid carcinomas are a diverse group representing high-grade transformation of the other types. In addition to a description of the pathologic findings, there is a discussion of tumor markers and prognostic indicators. The clinical significance of the classification is discussed, with reference to recent reports.

Entities:  

Mesh:

Year:  2002        PMID: 12084216     DOI: 10.1007/s11934-002-0007-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  25 in total

1.  Renal cell carcinoma with rhabdoid features.

Authors:  N Gökden; O Nappi; P E Swanson; J D Pfeifer; R T Vollmer; M R Wick; P A Humphrey
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

2.  Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.

Authors:  A Zisman; A J Pantuck; D Chao; F Dorey; J W Said; B J Gitlitz; J B de Kernion; R A Figlin; A S Belldegrun
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

3.  Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.

Authors:  A K Avery; J Beckstead; A A Renshaw; C L Corless
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

4.  Collecting duct renal cell carcinoma: clinical study of a rare tumor.

Authors:  Debby Chao; Amnon Zisman; Allan J Pantuck; Barbara J Gitlitz; Stephen J Freedland; Jonathan W Said; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

Review 5.  Histopathology and molecular genetics of renal tumors toward unification of a classification system.

Authors:  N R Zambrano; I A Lubensky; M J Merino; W M Linehan; M M Walther
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

6.  Renal cell carcinoma of end-stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification.

Authors:  M D Hughson; S Bigler; K Dickman; G Kovacs
Journal:  Mod Pathol       Date:  1999-03       Impact factor: 7.842

7.  Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.

Authors:  P Chu; E Wu; L M Weiss
Journal:  Mod Pathol       Date:  2000-09       Impact factor: 7.842

Review 8.  Collecting duct carcinoma of kidney.

Authors:  J R Srigley; J N Eble
Journal:  Semin Diagn Pathol       Date:  1998-02       Impact factor: 3.464

9.  Immunohistochemical detection of CD10 in paraffin sections of hematopoietic neoplasms: a comparison with flow cytometry detection in 56 cases.

Authors:  P G Chu; K L Chang; L M Weiss; D A Arber
Journal:  Appl Immunohistochem Mol Morphol       Date:  2000-12

10.  Collecting duct carcinomas of the kidney: a comparative loss of heterozygosity study with clear cell renal cell carcinoma.

Authors:  F Fogt; Z Zhuang; W M Linehan; M J Merino
Journal:  Oncol Rep       Date:  1998 Jul-Aug       Impact factor: 3.906

View more
  2 in total

1.  Renal cell carcinoma: diagnosis and treatment, 1994-2003.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

2.  Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.

Authors:  Giuseppe Rosiello; Carlotta Palumbo; Sophie Knipper; Angela Pecoraro; Stefano Luzzago; Pierre-Antoine St-Hilaire; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz
Journal:  World J Urol       Date:  2020-04-06       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.